Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) traded down 2.9% during trading on Wednesday . The stock traded as low as $7.18 and last traded at $7.24, with a volume of 60,278 shares. The stock had previously closed at $7.46.

A number of brokerages have recently issued reports on ADAP. Leerink Swann reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics PLC – in a report on Sunday, April 24th. Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC – from a “hold” rating to a “buy” rating and set a $9.75 target price on the stock in a report on Tuesday, July 12th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Adaptimmune Therapeutics PLC – has an average rating of “Buy” and a consensus target price of $15.94.

The stock’s 50 day moving average price is $8.11 and its 200 day moving average price is $8.64. The stock’s market cap is $512.48 million.

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.16. Equities analysts predict that Adaptimmune Therapeutics PLC – will post ($1.16) earnings per share for the current year.

In other news, Director Orbimed Advisors Llc purchased 1,712,400 shares of the business’s stock in a transaction that occurred on Tuesday, May 24th. The shares were acquired at an average cost of $10.42 per share, for a total transaction of $17,843,208.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

A hedge fund recently bought a new stake in Adaptimmune Therapeutics PLC – stock. Marshall Wace LLP acquired a new stake in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 140,983 shares of the company’s stock, valued at approximately $1,700,000. Marshall Wace LLP owned 0.20% of Adaptimmune Therapeutics PLC – as of its most recent SEC filing.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.